1649: Spectict Capromab Pendetide Independently Predicts BDFS in Long Term Outcome Study

Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide

“…As previously demonstrated in the literature (6), our series also confirm the increased risk of BF in patients with higher-risk profiles. Secondly, our data suggest that molecular imaging, using SPECT/CT ProstaScint, independently predicts for an increased risk of bDFS failure (39).…”